Quarterly ResultNov 4, 2026, 08:31 AM
Ocugen Q3 Net Loss $3.6M; OCU400 Bahamas Approval; OCU410 Phase 3 Begins
AI Summary
Ocugen, Inc. announced its third quarter 2026 financial results, reporting a net loss of $3.6 million, an improvement from the $20.1 million net loss in the same period last year. The company ended the quarter with $84.6 million in cash and investments, projecting a runway into 2028. Key business updates include the initiation of the Phase 3 ArMaDa3 trial for OCU410, provisional approval for OCU400 in The Bahamas, and an exclusive license agreement for OCU400 in the MENA region. Top-line data for the OCU400 Phase 3 trial is anticipated in Q1 2027.
Key Highlights
- Ocugen reported a net loss of $3.6 million for Q3 2026, compared to a net loss of $20.1 million in Q3 2025.
- Cash, cash equivalents, restricted cash, and short-term investments totaled $84.6 million as of September 30, 2026, with an expected runway into 2028.
- Initiated dosing in Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA).
- Received Provisional Approval and Priority Designation for OCU400 in The Bahamas.
- Executed an exclusive OCU400 license agreement for the Middle East and North Africa (MENA) with Roots Pharmaceutical.
- Top-line data from the Phase 3 liMeliGhT trial for OCU400 are expected in Q1 2027.
- Total operating expenses for Q3 2026 were $19.7 million, including $12.5 million for R&D and $7.2 million for G&A.
Price Impact
More from OCGN